Investorideas.com newswire, breaking biotechnology and pharma news

Monday, November 9, 2020

#COVID19 Second Wave? From #Sanitizers to #PPE’s, Companies are Preparing (OTC: $HIPH) (OTC: $OPTI) (OTC: $ATWT) (OTC: $RLLVF) @AmericanPremium @optecfuelintl @AtwecTech @RELEVIUMCORP

#COVID19 Second Wave? From #Sanitizers to #PPE’s, Companies are Preparing (OTC: $HIPH) (OTC: $OPTI) (OTC: $ATWT) (OTC: $RLLVF) @AmericanPremium @optecfuelintl @AtwecTech @RELEVIUMCORP

 


Point Roberts WA, Delta, BC – November 9, 2020 - Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a special report on the continued growth of the sanitation and PPE sectors as businesses around the world look to supply the new COVID reality and prepare for a potential second wave.

 

Read this news, featuring HIPH in full at https://www.investorideas.com/news/2020/main/11091COVID-19-Second-Wave.asp

 

While COVID-19 has impacted many businesses both negatively and positively, as we enter into the colder seasons many companies are using this time to bring new sanitation and PPE products to market in anticipation of another rise in demand as well as to help prevent further spread of the pandemic.

 

American Premium Water Corporation (OTC: HIPH) recently announced that it has begun production on the first run of proprietary nano-infused products through its distribution agreement with BioHealth Water Inc., a wholly owned subsidiary of Alset International Limited (SGX:40V). The initial production run marks the beginning of the Company’s efforts to sell its aerosolized sanitizing machines in addition to its two new products utilizing its proprietary Hydro Nano technology: Nano Energy Water and Nitrous Oxide Shots. The products are in the process of applications for product distribution in Malaysia, Hong Kong, Taiwan, Singapore, USA and Canada.

 

Ryan Fishoff, CEO of American Premium Water commented, “I am excited to announce the beginning of production for our new products with our new partner in BioHealth Water. This first run will get the products into the hands of distributors across the Pacific Rim (North America & Asia). We are only scratching the surface of the potential that we have with BioHealth Water and I look forward to receiving feedback from our distributors as we prepare for full scale production later this year. Our plans to increase the volume of distribution alongside various other initiatives that we intend to achieve in the remaining quarter of 2020 will set a firm platform for us to move full steam into 2021. As I have been emphasizing over the years, I believe this partnership highlights the value of the Company’s Hydro Nano technology. We are exploring even more ways to unlock value from this technology, and I look forward to sharing these developments with shareholders in the coming weeks and months.”

 

The Company previously announced in April that it had developed a prototype of an aerosolized sanitizing machine using its proprietary Hydro Nano technology. This production run will be the first run of the devices and its accompanying sanitizing nano-solution. All products will be sold through HWH global distributors (www.hwhworld.com) and direct sales in the respective countries.

 

Chan Heng Fai, Chairman and CEO of Alset commented, “I am very excited to begin selling these products across our global distribution channels. All three products have the potential to make an extraordinary impact that I believe will translate well to the consumer and drive sales. I see a tremendous opportunity with the sanitizing machine to assist small businesses that are looking for an effective solution to bring customers back through the door. I am also looking forward to bringing Nano Energy Water to market, which I believe will make a big impact with customers. I look forward to working with Ryan and his team to continue growing distribution and bring even more impactful products to market in the coming years.”

 

OPTEC International, Inc (OTC:OPTI) announced recently that it has successfully secured a fully executed definitive agreement for the supply of Brand Specific Personal Protection Equipment (PPE) products for a large International Commodities Consortium totaling in excess of $2 Billion Dollars US.

 

OPTEC CEO, Roger Pawson commented "The company has been working for over a month to bring the transaction to successful closing and we are extremely happy to announce the execution of the definitive agreement and preparation of the massive logistics operation for the distribution of the products, furthermore OPTEC has entered into an additional agreement with an established Freight and Logistics organization for the transportation of products to the final destinations in the Healthcare, Medical, and Hospital sectors.

 

Item 1.01 Entry into A Material Definitive Agreement.

  1. If the registrant has entered into a material definitive agreement not made in the ordinary course of business of the registrant, or into any amendment of such agreement that is material to the registrant, disclose the following information:

 

On October 30, 2020 the Company (OPTEC) entered into a definitive agreement with a large International Commodities Consortium for the supply and distribution of Specific Brands of Personal Protection Equipment (PPE) for Medical & Hospital use throughout North America, totaling in excess of Two Billion Dollars $US. The agreement has been fully executed by the company and the buyer, along with proofed bank certified funds to complete the transaction in excess of $2 Billion Dollars US. The company (OPTEC) has already sourced and secured the products for the entire agreement, along with coordinating the logistics portion of the agreement. The product distribution is expected to be fully completed by December 2020.

 

Another company based in health and wellness like American Premium Water, Relevium Technologies Inc. (TSX.V: RLV) (OTC: RLLVF), announced in September that its wholly-owned subsidiary in the US, BGX E-Health LLC, had secured up to eight chartered flights to deliver USD$16.9 Million of critical PPE to the Canadian Health Care Market, which arrived over the next 7-10 days in Canada.

 

On September 17, 2020, the Company announced it had secured an initial contract totaling USD$20 million of critical PPE aimed for the Canadian healthcare market. The Company is now focused on the delivery of this initial contract, as we all, on pursuing new opportunities in the space.

 

This initial delivery represented approximately 75% of the initial previously announced contract.

 

BGX E-Health, the Company’s US wellness subsidiary has pivoted into the Emergency Segment of the Health and Wellness market by launching its own line of hand sanitizers and developing air purifier solutions. In the early summer months of this year, the Company identified an opportunity to make a difference in the supply of critical PPE and on July 13, 2020 the company announced a joint venture between Relevium and H-Source to join forces to bring critical PPE to the areas in need in a secure and traceable platform.

 

Aurelio Useche, CEO of Relevium stated, “Our team has been on site in the US sourcing both, local and overseas supplies of critical PPE and we are pleased to announce the scheduling of several airfreight charts to deliver the urgently products on a timely basis. We now set our sights on further development of this space as we expand our customer base in conjunction with our partners.”

 

This industry is attracting attention from businesses from all sectors. Even child safety and security company, ATWEC Technologies (OTC: ATWT) announced that it is giving transportation companies and passengers yet another layer of protection. The company has introduced the KV-X Sterilization System, a new automated, two-stage sterilization system for school buses, daycare vans, and other commercial vehicles that kills germs, viruses, and bacteria in the air and on vehicle surfaces quickly, safely and effectively.

 

Built for 15-passenger vehicles or larger, the KV-X features a 30-minute, two-stage sanitization module that adheres to all FDA guidelines. When the KV-X system is initiated, a built-in induction fan draws air through an easily replaceable HEPA filter and into a self-contained ultraviolet light (UVC) to disinfect the air within the vehicle. During the next stage, ozone is generated to clean seats, door handles, and other high-touch internal surfaces. UVC and ozone have been scientifically tested and used for years to kill airborne and surface germs and viruses.

 

The KV-X comes with a built-in timer, enabling users to schedule the system to self-start at a pre-designated time, typically overnight, to ensure vehicles are properly sanitized for next-day use. An always-on motion sensor (the same technology that powers ATWEC's KV-4 Child Reminder System) confirms a vehicle is empty before the KV-X sterilization cycle can begin. If the KV-X detects motion during the cycle, it will immediately shut down the system to prevent direct passenger exposure to the ozone and UVC.

 

"When it comes to transportation, our mission is to ensure the safest ride for each child, passenger and driver. In today's environment, expanding our product line into vehicle sanitization was obvious," said Darnell Stitts, President and CEO at ATWEC Technologies. "The KV-X Sterilization System is a safe, fast, and efficient way for school systems, daycare organizations, commercial transportation services, and even public transportation agencies to give passengers and their families peace of mind and a cleaner, healthier riding experience."

 

The KV-X can be installed in any 15-passenger vehicle or larger. It is more efficient than traditional manual aerosol mist applications and it does not rely on a vehicle's air conditioning system to operate. This process allows the vehicle to be sanitized quickly and be back into operation sooner.

 

As governments around the world struggle to provide adequate sanitation and PPE equipment to hospitals and essential workers, the public sector continues to capitalize on this market growth opportunity and through new innovations is helping to ensure that customers have access to adequate sanitation and PPE equipment in a post COVID world.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others. 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this news article featuring HIPH is a paid for news release on Investorideas.com –More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800-665-0411

 

 

 

 

 



 

 

Thursday, November 5, 2020

#Health and Wellness #Stock #Alert: Electromedical Technologies, Inc. (OTCQB: $EMED) and Energetic Wellness School of Naturopathy Announce Collaborative Certification Program @ElectromedicalT

 

#Health and Wellness #Stock #Alert: Electromedical Technologies, Inc. (OTCQB: $EMED) and Energetic Wellness School of Naturopathy Announce Collaborative Certification Program @ElectromedicalT

 

FDA cleared WellnessPro designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation

 

SCOTTSDALE, Arizona November 5, 2020 - (Investorideas.com Newswire) – Breaking Medical Technology stock news - Electromedical Technologies, Inc. (OTCQB: EMED)  (the “Company”), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro®, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce a collaboration with Energetic Wellness School of Naturopathy to develop a new distribution platform and certification training program to onboard new medical device representatives and improve training for current Wellness Pro ambassadors.

 

Read this news featuring EMED in full at https://www.investorideas.com/news/2020/biotech/11051Electromedical-Technologies.asp

 

Dr. Michele Menzel, ND, D.psc, commented: “We are excited to work with Electromedical Technologies to develop and establish a curriculum/certification program that will include bioelectronics applications such as frequencies used, treatment protocols and treatment techniques, as well as books and materials for students and distributors.

 

Doctors and patients are realizing the importance of using methods that will have a positive effect in reducing pain without having negative effects on the immune system, especially in today’s pandemic environment. We will make this course available to our students, alumni distributors or anyone interested in the future of medicine to have an opportunity to take our course.”

 

Matthew Wolfson, CEO of Electromedical Technologies, commented, “This program fits perfectly with our plan of engaging and onboarding hundreds of new medical practitioners and distributors. In today’s economic environment, many people are seeking to create new revenue streams for their families. We have a way to help thousands of people to live a better quality of life, pain free and addiction free and at the same time provide a real income opportunity for anyone who wishes to join our brand ambassador team.” (https://electromedtech.com/register/)

 

The new Master Device Rep program will provide our current device representatives with added bonuses and give interested people who wish to join our team an incredible business opportunity as well. This certification program and curriculum are pending approval.

 

Energetic Wellness School of Naturopathy is located in Edmond, OK https://energeticwellnessok.com/. Its Alumni, health providers, their patients and clients will have access to training and certification in the area of bioelectronics and specifically will have access and training using the Wellness Pro® Plus device and future product line.

 

Dr. Lee Woolley, DNM, GNM, MBnC, commented: “The Wellness Pro® Plus device has a proven track-record with over 10 years of positive results. We have tested and researched various devices on the market and have not seen any device produce such powerful and long-term pain-relieving effects. That is why we chose to work with Electromedical to provide our students and new healthcare providers access and training on one of the best devices on the market today – The Wellness Pro® Plus.

 

We cannot wait for the company to release its new Wellness Pro® POD next year. This will be a game changer for practitioners to provide safer pain relief choices for their patients.

Since provider education is imperative in the effective usage of non-invasive, non-toxic bio-electronic wellness methodologies, training assists providers in understanding the foundation, application, research and various methods in effective pain care and management at home and in the office.  It is a great tool for future doctors to be able to run various programs for their patients at their home or office.”

 

Finally, Mr. Wolfson commented, “It was very important to collaborate with such a great institution as the Energetic Wellness School of Naturopathy so that more practitioners and distributors may gain comprehensive knowledge of Bioelectronics, and  modern effective medical devices and technologies that produce natural pain relief and overall wellness. Doctors and students will have access to the Wellness Pro® Plus devices, which will give them hands on understanding of the various techniques and benefits of using drug free application techniques for chronic, acute post traumatic and intractable pain. Bioelectronics will Electrify medicine in the next 5 years and will be the norm in treatments of not only Chronic pain but will also one day open doors to other treatments that will improve human well-being without addictive and harmful side effects. Electromedical (EMED) is part of the wave of the future."

 

About Electromedical Technologies:

Headquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is an FDA cleared  commercial stage bioelectronic medical device manufacturing and distribution company initially focused on the treatment of various chronic, acute, intractable and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

 

For more information, visit https://electromedtech.com

 

Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare.  The United States Food and Drug Administration has not reviewed or approved our animal research studies.

 

Safe Harbor Statement:

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Electromedical Technologies, Inc.
Matthew Wolfson
Tel: 1.888.880.7888
email:
ceo@electromedtech.com
www.electromedtech.com

 

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring Electromedical Technologies, Inc. (OTCQB: EMED)  is a paid for news release on Investorideas.com  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory 

Get News Alerts on Biotech Stocks

 

#AI #Stock News: GBT Tokenize (OTCPINK: $GTCH) to Add Blood Pressure Measurement Feature to qTerm Device - Version II Aim to Release Q1/2021 @GbtTechnologies #artificialintelligence

 #AI #Stock News: GBT Tokenize (OTCPINK: $GTCH) to Add Blood Pressure Measurement Feature to qTerm Device  - Version II Aim to Release Q1/2021 @GbtTechnologies #artificialintelligence

 


San Diego, CA, November 5, 2020 - (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH) ("GBT”, or the “Company”), announced that its joint Venture GBT Tokenize Corp (“GBT/Tokenize”) is currently developing an additional feature for its qTerm device. The additional feature will be a blood pressure measurement system and it is planned to be released with the product's second release during Q1 2021.

 

Read this in full at https://www.investorideas.com/CO/GOPH/news/2020/11051qTerm-Blood-Pressure-Measurement.asp

 

Typical blood-pressure apparatus is built using bulky and mechanical cuff-based medical devices. qTerm is planned to introduce a solid-state based blood-pressure monitoring solution, in order to enable a more convenient measurement system that will make tracking and monitoring easier. Cardiovascular disease is a leading factor of death and disability, and elevated blood pressure is a major contributor to these types of health risks. Early detection of hypertension can alert users to follow with appropriate therapy and treatment.

 

GBT/Tokenize’s blood pressure solution will comprise a complete integrated optical sensor module, and an embedded microcontroller. A sensing firmware algorithm will provide the operation and control of the entire system. Such method is called photoplethysmography (PPG) and its goal is to detect blood volume changes in the microvascular tissues. qTerm users will be able to measure blood pressure simply by placing their finger on the device while resting, at any time and anywhere.

 

The Optical Blood Pressure analysis system works by illuminating the finger's skin with miniature LED light (Emitted by the sensing system, and controlled by the embedded microcontroller) and by further capturing the light that is scattered and modulated by the pulsation of the user's skin arterioles. These signals are fed into algorithms to mathematically calculate the body's blood pressure. qTerm device will be enhanced by the addition of a high-sensitivity optical sensor and microchip on its PCB board. The physical dimensions of the device are expected to grow slightly. GBT is currently evaluating advanced optical electronic systems. An integrated optical solution consumes low power and provides high accuracy. The device also received its TM (Trademark) allowance notice and will present it on the product/package as required by the United State Patent Office. The qTerm device is targeted to measure body temperature, blood pressure, blood oxygen level and heart rate – all with a simple touch of the finger.

 

In order to assist with the world's current situation, GBT/Tokenize has decided to introduce an initial release of qTerm. The early release of the product will include body temperature, heart rate and blood oxygen level features and is targeted to be released by the end of this year. These three (3) vitals measurements are essential to assist with the pandemic crisis since they provide important health factors for early viral infection detection. The Blood Pressure feature is planned to be released in qTerm second release, planned for Q1 2021.

"Our qTerm device was planned to provide major human vitals, one of them is blood pressure. We decided to rush our first version to the market in order to assist with the global pandemic. As qTerm general development is continuing we are now developing its originally planned feature; blood pressure. Using a digital embedded sensor electronic system, and machine-learning algorithms we develop an embedded optical based analysis system to measure blood pressure. This miniature system will be based on photophlethysmography (PPG) method and installed within our qTerm medical device" stated Danny Rittman, GBT’s CTO. "qTerm will measure the amount of light that is absorbed or reflected by blood vessels in human tissues, calculating responsive changes in the blood's volume. The sensor coverage area includes veins, arteries, and numerous capillaries. Software algorithm will calculate and conclude the numerical results. qTerm will include blood oxygen level, heart rate, body temperature and blood pressure vitals measurements and all with a touch of a finger, a none-invasive product. Users will be able to potentially monitor their health, potentially identify early signs of health issues, and take appropriate care. Blood pressure is a critical vital to address proper treatment and management. Many medical conditions require this data and qTerm will be offering an easy, convenient measurement capability that will enable users to take the time and potentially monitor their health frequently. No bulkier cuffs and discomfort measurement devices, but a simple none-invasive touch of a finger will make the process of blood pressure measurement comfortable, easier and faster. High blood pressure is associated with many chronic disease conditions, and is a major source of mortality and disabilities around the world. The device mobile app will support the additional feature by recording and analyzing the data. We strongly believe that this feature will be a significant addition to the qTerm device, making it a comprehensive, easy for use, mainly intuitive, medical device. We plan to expand the device furthermore the future, adding more features and AI analysis capabilities" continued Dr. Rittman.

 

About GBT Technologies Inc.

GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is 
a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms.  GBT has a portfolio of Intellectual Property that, if commercialized, is designed to include smart microchips, mobile and security applications and protocols and supporting cloud software.  GBT’s system envisions the creation of a global mesh network.  The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. GBT envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
GBT Technologies Inc.

Media: press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 


Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 




BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory 

Get News Alerts on Biotech Stocks

 

Wednesday, November 4, 2020

#Medical #Technology #Stock Alert: Electromedical Technologies, Inc. (OTCQB: $EMED) and Energetic Wellness School of Naturopathy Announce Collaborative Certification Program in “Bioelectronics Therapist and Master Device Technician” @ElectromedicalT

 

#Medical #Technology #Stock Alert: Electromedical Technologies, Inc. (OTCQB: $EMED) and Energetic Wellness School of Naturopathy Announce Collaborative Certification Program in “Bioelectronics Therapist and Master Device Technician” @ElectromedicalT

 

Expand Product Awareness and on Boarding of NEW Device Representatives and Brand Ambassadors



SCOTTSDALE, Arizona November 4, 2020 -
(Investorideas.com Newswire) – Breaking Medical Technology stock news - Electromedical Technologies, Inc. (OTCQB: EMED)  (the “Company”), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro®, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce a collaboration with Energetic Wellness School of Naturopathy to develop a new distribution platform and certification training program to onboard new medical device representatives and improve training for current Wellness Pro ambassadors.

 

Read this news featuring EMED in full at https://www.investorideas.com/news/2020/biotech/11041EMED-Bioelectronics-Therapist-Master-Device.asp

 

Dr. Michele Menzel, ND, D.psc, commented: “We are excited to work with Electromedical Technologies to develop and establish a curriculum/certification program that will include bioelectronics applications such as frequencies used, treatment protocols and treatment techniques, as well as books and materials for students and distributors.

 

Doctors and patients are realizing the importance of using methods that will have a positive effect in reducing pain without having negative effects on the immune system, especially in today’s pandemic environment. We will make this course available to our students, alumni distributors or anyone interested in the future of medicine to have an opportunity to take our course.”

 

Matthew Wolfson, CEO of Electromedical Technologies, commented, “This program fits perfectly with our plan of engaging and onboarding hundreds of new medical practitioners and distributors. In today’s economic environment, many people are seeking to create new revenue streams for their families. We have a way to help thousands of people to live a better quality of life, pain free and addiction free and at the same time provide a real income opportunity for anyone who wishes to join our brand ambassador team.” (https://electromedtech.com/register/)

 

The new Master Device Rep program will provide our current device representatives with added bonuses and give interested people who wish to join our team an incredible business opportunity as well. This certification program and curriculum are pending approval.

 

Energetic Wellness School of Naturopathy is located in Edmond, OK https://energeticwellnessok.com/. Its Alumni, health providers, their patients and clients will have access to training and certification in the area of bioelectronics and specifically will have access and training using the Wellness Pro® Plus device and future product line.

 

Dr. Lee Woolley, DNM, GNM, MBnC, commented: “The Wellness Pro® Plus device has a proven track-record with over 10 years of positive results. We have tested and researched various devices on the market and have not seen any device produce such powerful and long-term pain-relieving effects. That is why we chose to work with Electromedical to provide our students and new healthcare providers access and training on one of the best devices on the market today – The Wellness Pro® Plus.

 

We cannot wait for the company to release its new Wellness Pro® POD next year. This will be a game changer for practitioners to provide safer pain relief choices for their patients.

Since provider education is imperative in the effective usage of non-invasive, non-toxic bio-electronic wellness methodologies, training assists providers in understanding the foundation, application, research and various methods in effective pain care and management at home and in the office.  It is a great tool for future doctors to be able to run various programs for their patients at their home or office.”

 

Finally, Mr. Wolfson commented, “It was very important to collaborate with such a great institution as the Energetic Wellness School of Naturopathy so that more practitioners and distributors may gain comprehensive knowledge of Bioelectronics, and  modern effective medical devices and technologies that produce natural pain relief and overall wellness. Doctors and students will have access to the Wellness Pro® Plus devices, which will give them hands on understanding of the various techniques and benefits of using drug free application techniques for chronic, acute post traumatic and intractable pain. Bioelectronics will Electrify medicine in the next 5 years and will be the norm in treatments of not only Chronic pain but will also one day open doors to other treatments that will improve human well-being without addictive and harmful side effects. Electromedical (EMED) is part of the wave of the future."

 

About Electromedical Technologies:

Headquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is an FDA cleared  commercial stage bioelectronic medical device manufacturing and distribution company initially focused on the treatment of various chronic, acute, intractable and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

 

For more information, visit https://electromedtech.com

 

Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare.  The United States Food and Drug Administration has not reviewed or approved our animal research studies.

 

Safe Harbor Statement:

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Electromedical Technologies, Inc.
Matthew Wolfson
Tel: 1.888.880.7888
email:
ceo@electromedtech.com
www.electromedtech.com

 

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring Electromedical Technologies, Inc. (OTCQB: EMED)  is a paid for news release on Investorideas.com  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 


BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory 

Get News Alerts on Biotech Stocks